Xlife Sciences AGXSWX:XLS -11.06%50 Net Margin % is 23,413.92% as of Dec. 2025, which is 1455% above its 10-year median of 1,505.97. GuruFocus rates XSWX:XLS with a GF Score™ of 50/100 and a GF Value™ of CHF7.30 (Significantly Overvalued). The stock has 13 warning signs investors should review. Among 947 Biotechnology companies, Xlife Sciences AG ranks worse than 92.08% on this metric.
The historical rank and industry rank for Xlife Sciences AG's Net Margin % or its related term are showing as below:
XSWX:XLS'
s Net Margin % Range Over the Past 10 Years
Min: -7835.27 Med: 1505.97 Max: 6627.54
Current: -7835.27
XSWX:XLS's Net Margin % is ranked worse than 92.08% of 947
companies
in the Biotechnology industry
Industry Median: -89.33
vs XSWX:XLS: -7835.27
Xlife Sciences AG (XSWX:XLS) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Xlife Sciences AG Net Margin % Related Terms
Xlife Sciences AG Net Margin % Historical Data
* Premium members only.
The historical data trend for Xlife Sciences AG's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:XLS vs VRTX, REGN, ALNY: Net Margin % Comparison
For the Biotechnology subindustry, Xlife Sciences AG's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xlife Sciences AG Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xlife Sciences AG's Net Margin % distribution charts can be found below:
* The bar in red indicates where Xlife Sciences AG's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xlife Sciences AG (XSWX:XLS) has a Net Margin % of 23,413.92% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Xlife Sciences AG and its competitors. This is 1455% above median its historical median of 1,505.97. According to the industry distribution chart, Xlife Sciences AG ranks #872 out of 947 companies in the Biotechnology industry, placing it in the top 92.1%.
Is Xlife Sciences AG's Net Margin % too high?
Xlife Sciences AG's current Net Margin % of 23,413.92% is 1455% above median its 10-year median of 1,505.97. Based on the distribution chart, Xlife Sciences AG ranks #872 out of 947 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Xlife Sciences AG has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xlife Sciences AG's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Xlife Sciences AG ranks #872 out of 947 companies for Net Margin %. This places Xlife Sciences AG in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Xlife Sciences AG and its competitors. Xlife Sciences AG's current Net Margin % is 23,413.92%, which is 1455% above median its own 10-year median of 1,505.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xlife Sciences AG stock overvalued right now?
Based on GuruFocus' analysis, Xlife Sciences AG (XSWX:XLS) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF7.30, compared to a current price of CHF20.90 — trading 186.3% above its estimated fair value. The current Net Margin % is 23,413.92%, which is 1455% above median its 10-year median of 1,505.97. Xlife Sciences AG's overall GF Score™ is 50/100 with 13 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Xlife Sciences AG (XSWX:XLS), the current Net Margin % is 23,413.92% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xlife Sciences AG (XSWX:XLS) Overvalued in 2026?
Based on GuruFocus' analysis, Xlife Sciences AG stock appears to be overvalued.
The current stock price of CHF20.90 is trading 186.3% above its estimated GF Value™ of CHF7.30.
GuruFocus considers Xlife Sciences AG to be Significantly Overvalued.
Key valuation signals for XSWX:XLS:
Net Margin %: 23,413.92% (1455% above median its 10-year median of 1,505.97)
GF Value™: CHF7.30 vs. price of CHF20.90 (186.3% above fair value)
No single metric tells the full story. See the XSWX:XLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high-unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments, which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial Intelligence/Digital Medicine.
50GF Score
Get the complete analysis for XSWX:XLS
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:XLS has been successfully added to your 
